Here are the Form 4 insider transactions from Quest Diagnostics Inc. (DGX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DGX filings page.
Quest Diagnostics Inc. reported that SVP, Regional Businesses Subu Ramachandran received an award of 1,386 stock options to acquire common stock at an exercise price of $248.61 per share on November 3, 2026. The award also included 352 restricted share units; direct common-stock holdings following that award were 2,832 shares. The options vest in three equal annual installments beginning on the first anniversary of the grant date and expire on November 3, 2036.
Quest Diagnostics Inc. Executive Vice President Catherine T. Doherty exercised options for 22,105 shares at $121.8050 per share on November 3, 2026; the reported option balance afterward was 0. She received 4,827 restricted stock units and sold 22,105 shares that day under a Rule 10b5-1 sales plan she adopted. The seven weighted-average sale prices were 3,818 at $245.4519, 5,990 at $246.2649, 1,151 at $246.9835, 2,358 at $248.3838, 3,004 at $249.4035, 2,877 at $250.4882, and 2,907 at $251.2386 per share. A separate indirect holding entry reports 4,552 shares through the Company's 401(k) and/or Supplemental Deferred Compensation Plan; the count is based on the company stock-fund account balance, which includes some money market instruments.
Quest Diagnostics (DGX) reported that Mark E. Delaney, SVP & Chief Commercial Officer, acquired 2,615 shares of common stock on November 3, 2026, through an award of restricted stock units. His reported direct holdings following the award were 12,975 shares.
Quest Diagnostics Inc. (DGX) director Gary M. Pfeiffer sold 1,203 shares of common stock at $243 per share on October 26, 2026. The sale was effected pursuant to a Rule 10b5-1 sales plan adopted by Gary M. Pfeiffer. He directly held 29,802 shares after the transaction.
Quest Diagnostics Inc. (DGX) director Robert B. Carter acquired 10 shares of common stock at $235.93 per share on October 21, 2026, through a dividend reinvestment plan administered by his broker. His directly held position was 3,874 shares after the transaction. The shares were eligible for deferred reporting under Rule 16a-6, and Carter chose to report the acquisition early.
Quest Diagnostics Inc. executive vice president and CFO Sam Samad acquired 90 common shares on October 21, 2026, at $235.9390 per share through a dividend reinvestment plan administered by his broker. He directly held 33,568 shares after the acquisition.
Quest Diagnostics Inc. director Vicky B. Gregg acquired 63 shares of common stock on October 21, 2026, at $235.9390 per share through a dividend reinvestment plan administered by the reporting person's broker. The reported directly held position following the acquisition was 18,449 shares. The shares were eligible for deferred reporting on Form 5 under Rule 16a-6, and Gregg chose to report the transaction early on Form 4.
Quest Diagnostics SVP, Clinical Solutions Karthik Kuppusamy acquired 33 common shares at $235.9440 per share on October 21, 2026, through a dividend reinvestment plan administered by his broker. His reported direct holdings after the transaction were 13,619 shares, including exempt purchases under the company’s stock purchase plan since his prior Form 4. The report also lists 358 shares held by a trust and 1,697 shares associated with the company’s 401(k) plan; the latter figure is based on the plan’s stock-fund account balance, which includes some money-market instruments.
Quest Diagnostics (DGX) director Wright Lassiter III acquired 6 common shares on October 21, 2026, at $235.9590 per share through a dividend reinvestment plan administered by his broker. His direct holdings after the transaction were 10,329 shares. The acquisition was eligible for deferred reporting on Form 5 under Rule 16a-6, but he chose to report it early on Form 4. No Rule 10b5-1 plan is reported.
Quest Diagnostics Inc. (DGX) SVP for Diagnostic Services Patrick Plewman acquired 41 common shares on October 21, 2026, at $235.94 per share through a dividend reinvestment plan administered by his broker. He directly held 15,334 shares after the transaction. The acquisition was eligible for deferred reporting under Rule 16a-6 but was reported early. No Rule 10b5-1 plan is reported.
Quest Diagnostics Inc. (DGX) director Timothy L. Main acquired 18 common shares on October 21, 2026, at $235.9370 per share through a dividend reinvestment plan administered by his broker. The transaction was eligible for deferred reporting under Rule 16a-6, and he chose to report it early; no Rule 10b5-1 plan is reported. After the acquisition, he directly held 22,478 shares and held 5,000 shares indirectly through a trust.
Quest Diagnostics Inc. (DGX) reported a 25-share common-stock acquisition by SVP & Chief Commercial Officer Mark E. Delaney on October 21, 2026, at 235.9410 per share through a dividend reinvestment plan. His reported direct holdings following the transaction were 10,360 shares. No Rule 10b5-1 plan is reported.
Quest Diagnostics Inc. director Timothy C. Wentworth acquired 135 Phantom Stock Units on October 1, 2026, through elective deferrals of director cash compensation under the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors. His reported balance after the award was 477 Phantom Stock Units. The units become payable in cash upon termination of his service as a director.
QUEST DIAGNOSTICS INC (DGX) reported that CEO, President and director J. E. Davis sold 10,000 shares of common stock on September 1, 2026 at an average price of $242.72 per share in an open-market or private transaction. The transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the executive. Following this sale, Davis directly holds 122,423 shares of Quest Diagnostics common stock.
QUEST DIAGNOSTICS INC (DGX) disclosed that Michael E. Prevoznik, SVP & General Counsel, exercised 22,677 stock options at $112.17 per share into common stock and, on the same date, sold 16,010, 6,237 and 430 common shares at weighted average prices of $242.8755, $243.6275 and $244.5148, respectively. The exercised option position was reduced to 0, and he also made a 1,000‑share charitable gift of common stock. Following these transactions, 5,780 shares are held indirectly through the company’s 401(k)/Supplemental Deferred Compensation Plan. The exercise and sales were effected under a Rule 10b5‑1 sales plan adopted by the reporting person.
Quest Diagnostics Inc. executive Mark E. Delaney, SVP & Chief Commercial Officer, reported selling 1,600 shares of common stock on 2026-07-28 at an average price of $235.18 per share. The sale was executed under a Rule 10b5-1 sales plan, and he now directly holds 10,335 shares.
Quest Diagnostics executive Karthik Kuppusamy, SVP Clinical Solutions, reported a small acquisition of 37 shares of common stock at $206.807 per share under a broker-administered dividend reinvestment plan, eligible for deferred Form 5 reporting under Rule 16a-6 but reported early. His direct holdings total 13,557 shares, with additional indirect holdings of 358 shares in a trust and 1,691 shares in the company’s 401(k) Profit Sharing Plan.
Quest Diagnostics director Robert B. Carter reported a small acquisition of 11 shares of common stock on July 22, 2026 at $206.804 per share. The shares were acquired through a broker-administered dividend reinvestment plan under Rule 16a-6, bringing his direct holdings to 3,864 shares.
Quest Diagnostics Inc. director Vicky B Gregg reported acquiring 72 shares of common stock on 2026-07-22 through a dividend reinvestment plan administered by the reporting person's broker. The shares were credited at $206.8080 per share, bringing the reported direct holdings to 18,386 shares. The disclosure notes this dividend reinvestment transaction was eligible for deferred reporting on Form 5 under Rule 16a-6, but it was voluntarily reported earlier on Form 4.
Quest Diagnostics Inc. executive Patrick Plewman, SVP for Diagnostic Services, reported acquiring 46 shares of Common Stock on 2026-07-22 at $206.807 per share through a dividend reinvestment plan administered by his broker. After this small acquisition under Rule 16a-6, he directly holds 15,293 shares. The dividend reinvestment, which is eligible for deferred reporting on Form 5, has been voluntarily reported earlier on Form 4.
Quest Diagnostics director Timothy L. Main reported a small acquisition of 21 shares of common stock on 2026-07-22 at $206.81 per share. The shares were acquired through a broker-administered dividend reinvestment plan and are eligible for deferred reporting under Rule 16a-6, though he chose to report early. After this transaction, he directly holds 22,460 shares and indirectly holds 5,000 shares through a trust.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported an acquisition of 102 shares of Quest Diagnostics common stock on July 22, 2026, at $206.807 per share in a grant/award transaction, bringing his directly held position to 33,478 shares.
Footnotes state the security represents an award of restricted share units and that the shares were acquired through a dividend reinvestment plan administered by his broker, which is eligible for deferred reporting on Form 5 under Rule 16a-6 but was voluntarily reported early.
Quest Diagnostics Inc. director Wright Lassiter III reported a small acquisition of common stock. On 2026-07-22, he acquired 6 shares at $206.813 per share through a dividend reinvestment plan administered by his broker, increasing his direct holdings to 10,323 shares. The transaction was eligible for deferred reporting on Form 5 under Rule 16a-6, but he chose to report it early on Form 4. The Rule 10b5-1 checkbox was not marked as a trading plan.
Quest Diagnostics Inc. executive Mark E. Delaney, SVP & Chief Commercial Officer, reported a small acquisition of 34.0000 shares of common stock on 2026-07-22 at 206.8070 per share through a broker-administered dividend reinvestment plan, which is eligible for deferred reporting on Form 5 under Rule 16a-6 but was reported early. Following this transaction, his direct holdings total 11935.0000 shares. A footnote notes that the security is described as common stock but represents an award of restricted share units.
Quest Diagnostics director Timothy C. Wentworth reported a routine compensation-related transaction involving deferred equity-based awards. He received 144 Phantom Stock Units, representing an elective deferral of his director cash compensation under the company’s Amended and Restated Deferred Compensation Plan for Directors. Each unit is tied to Quest Diagnostics common stock and is payable in cash when his service as a director ends. Following this grant, he holds 342 Phantom Stock Units in total. This filing reflects a non-cash grant/award acquisition rather than an open-market stock purchase or sale.
Quest Diagnostics senior vice president Karthik Kuppusamy exercised stock options and sold shares in a pre-planned trade. On 2026-06-04, he exercised options for 4,827 shares at $121.805 per share and 3,320 shares at $127.725, acquiring 8,147 shares of common stock through derivative exercises.
That same day, he completed an open-market sale of 8,147 common shares at $200.00 per share pursuant to a Rule 10b5-1 sales plan, converting option value into cash in a pre-arranged manner. Following these transactions, he directly held 13,510 common shares, with additional indirect holdings of 358 shares in a trust and 1,721 shares through the company’s 401(k) profit sharing plan.
Quest Diagnostics CEO and President J. E. Davis reported an open-market sale of 10,000 shares of Common Stock on June 1, 2026 at a price of $194.14 per share.
After this transaction, Davis directly holds 132,423 shares of Quest Diagnostics Common Stock. The sale was carried out under a pre-arranged Rule 10b5-1 sales plan adopted by the reporting person, indicating it was scheduled in advance rather than timed discretionarily.
Quest Diagnostics director Robert B. Carter received an equity award in the form of restricted stock units. On May 20, 2026, he acquired 1,142 shares of Common Stock at a stated price of $0.00 per share, reflecting a grant or award rather than an open-market purchase.
After this award, Carter directly holds 3,853 shares of Quest Diagnostics common stock in total. The filing does not show any sales or derivative exercises, indicating this was a routine compensation-related equity grant to a board member rather than a trading decision in the market.
Gregg Vicky B reported acquisition or exercise transactions in this Form 4 filing.
Quest Diagnostics director Vicky B. Gregg received a compensation-related stock award. She was granted 1,142 shares of Quest Diagnostics common stock in the form of restricted stock units at no cash cost. Following this award, she directly holds 18,314 shares of Quest Diagnostics common stock.
Diaz Luis reported acquisition or exercise transactions in this Form 4 filing.
Quest Diagnostics director Luis Diaz received an equity grant in the form of restricted stock units. On May 20, 2026, he was awarded 1,142 shares of Quest Diagnostics common stock at no purchase price, increasing his directly held stake to 5,196 shares. This represents routine stock-based compensation rather than an open-market trade.
Quest Diagnostics director Timothy L. Main received an award of 1,142 shares of Common Stock in the form of restricted stock units on May 20, 2026. The award was granted at $0.00 per share as part of his compensation and is classified as a grant or award acquisition. Following this transaction, his directly owned Common Stock holdings increased to 27,439 shares.
Quest Diagnostics Inc. director Timothy C. Wentworth received an award of 1,142 shares of Common Stock in the form of restricted stock units. The grant carried a price of $0.00 per share and increased his directly owned holdings to 1,358 shares after the transaction.
The total also reflects shares previously acquired through dividend reinvestment under the Amended and Restated Deferred Compensation Plan for Directors, as noted in the footnotes. This is a compensation-related equity award rather than an open-market stock purchase or sale.
Quest Diagnostics director Tracey Doi received an equity award tied to her board service. She acquired 1,142 shares of Common Stock as a grant with no cash price per share, described in the footnotes as an award of restricted stock units. After this award and related dividend reinvestments, she directly holds 7,748 shares.
Quest Diagnostics director Timothy M. Ring received an award of 1,142 restricted stock units of common stock, classified as a grant or other acquisition with no cash price per share. After this award, he directly holds 31,140 shares, including shares acquired through dividend reinvestment under the Amended and Restated Deferred Compensation Plan for Directors.
Quest Diagnostics Inc. director Wright Lassiter III received an equity grant of 1,142 shares of common stock on May 20, 2026, reported as a restricted stock unit award. Following this grant, he directly holds 10,317 shares, which include shares acquired through dividend reinvestment under the Deferred Compensation Plan for Directors.
Quest Diagnostics director Denise M. Morrison received an award of 1,142 shares of Common Stock on May 20, 2026 as a grant of restricted stock units. The award was made at no cash cost per share and increased her direct holdings to 11,929 shares.
The total includes shares acquired through dividend reinvestment since her last Form 4 under the Amended and Restated Deferred Compensation Plan for Directors.
Quest Diagnostics Inc. director Gary M. Pfeiffer received an award of 1,142 restricted stock units of common stock on May 20, 2026 at no cash cost, as part of his director compensation. After this grant, his direct holdings total 31,005 shares, which include shares acquired through dividend reinvestment under the Amended and Restated Deferred Compensation Plan for Directors.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported an acquisition of 108 shares of common stock on April 20, 2026, at $194.698 per share. After this award, he holds 33,376 shares directly.
Footnotes state the transaction represents an award of restricted share units and reflects shares acquired through a dividend reinvestment plan administered by his broker, which he chose to report early rather than on a later Form 5.
Quest Diagnostics senior executive Patrick Plewman, SVP for Diagnostic Services, reported a small acquisition of company common stock. On April 20, 2026, he acquired 49 shares at $194.699 per share through a dividend reinvestment plan administered by his broker.
Following this transaction, Plewman directly holds 15,247 Quest Diagnostics shares. The filing notes that these dividend reinvestment plan shares are eligible for deferred reporting on Form 5 under Rule 16a-6, but he chose to report the acquisition early on this Form 4.
Quest Diagnostics director Vicky B. Gregg increased her direct holdings through a dividend reinvestment plan. On April 20, 2026, she acquired 68 shares of Quest Diagnostics common stock at $194.698 per share via a broker-administered dividend reinvestment program. Following this automatic acquisition, she directly owns 17,172 shares of common stock. The filing notes this dividend reinvestment transaction was eligible for deferred reporting on Form 5, but she chose to report it early on Form 4.
Quest Diagnostics director Robert B. Carter reported a small acquisition of company stock through a dividend reinvestment plan. On April 20, 2026, he acquired 7 shares of common stock at $194.699 per share, bringing his direct holdings to 2,711 shares.
The shares were acquired automatically under a broker-administered dividend reinvestment plan and are eligible for deferred reporting on Form 5 under Rule 16a-6. Carter chose to report this routine transaction early on Form 4.
Quest Diagnostics director Wright Lassiter III reported a small acquisition of company stock through a dividend reinvestment plan. On April 20, 2026, he acquired 6 shares of common stock at $194.699 per share, bringing his direct holdings to 9,063 shares after the transaction. The filing notes this dividend reinvestment transaction is eligible for deferred reporting under Rule 16a-6, but the director chose to report it early on Form 4.
Quest Diagnostics SVP Karthik Kuppusamy reported a small acquisition of 39 shares of common stock at $194.699 per share. The filing describes this as a small acquisition under Rule 16a-6 related to a dividend reinvestment plan. Following the transaction, he holds 13,490 shares directly, plus indirect holdings through a trust and the company’s 401(k) plan.
Quest Diagnostics senior executive Mark E. Delaney reported a small automatic share acquisition. On April 20, 2026, he acquired 37 shares of Quest Diagnostics common stock at $194.696 per share through a dividend reinvestment plan under Rule 16a-6. Following this transaction, he directly holds 11,901 common shares.
WENTWORTH TIMOTHY C reported acquisition or exercise transactions in this Form 4 filing.
Quest Diagnostics director Timothy C. Wentworth received an award of 198 phantom stock units linked to Quest Diagnostics common stock. These units were credited on account of his elective deferral of director cash compensation under the company’s Amended and Restated Deferred Compensation Plan for Directors and will be payable in cash when his service as a director ends.
WENTWORTH TIMOTHY C reported acquisition or exercise transactions in this Form 4 filing.
Quest Diagnostics director Timothy C. Wentworth received an equity award of 215 shares of Common Stock in the form of restricted stock units. The grant was reported at a price of $0.00 per share as compensation, not a market purchase. Following this award, his directly owned position reported in this filing is 215 shares.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported two stock transactions involving the company’s common stock. On a performance stock award settlement, he acquired 13,947 shares at $204.86 per share, increasing his direct holdings to 40,988 shares.
On the same date, 7,720 shares were disposed of at $204.86 per share, delivered back to Quest Diagnostics solely to cover tax withholding obligations related to that performance share award, leaving him with 33,268 directly owned shares after the tax-related disposition.
Quest Diagnostics EVP Catherine T. Doherty reported multiple stock transactions involving company common shares. On March 4, 2026, she acquired 11,364 shares as a performance stock award at $204.86 per share, approved under Rule 16b-3(d).
On the same date, 5,806 shares were disposed of back to Quest Diagnostics solely to cover tax withholding obligations from that award at $204.86 per share. On March 5, 2026, she executed an open-market sale of 5,558 shares at an average price of $206.21 per share pursuant to a pre-established Rule 10b5-1 sales plan.
After these transactions, she directly owned 67,122 common shares. She also indirectly held 4,502 shares through company 401(k) and supplemental deferred compensation plans, with amounts based on plan account balances and the market price of Quest Diagnostics stock.
Quest Diagnostics senior executive Mark E. Delaney reported stock-based compensation activity involving company common stock. On March 4, 2026, he acquired 5,682 shares of Quest Diagnostics common stock at a value of $204.86 per share through the settlement of a performance stock award approved under Rule 16b-3(d).
On the same date, 2,326 shares of common stock were disposed of back to Quest Diagnostics solely to cover tax withholding obligations related to that award, as indicated in the footnotes. Following these transactions, Delaney directly owned 11,864 shares of Quest Diagnostics common stock.
Quest Diagnostics senior executive Michael E. Prevoznick reported several share movements in Quest Diagnostics Inc. common stock. On March 5, 2026, he completed an open-market sale of 3,878 shares at $206.21 per share under a pre-arranged Rule 10b5-1 sales plan, leaving him with 37,557 directly held shares after that trade.
On March 4, 2026, he received a grant or award of 7,232 shares at a reference price of $204.86 per share, issued in settlement of a performance stock award that had been approved under Rule 16b-3(d). Also on that date, 3,354 shares were disposed of back to Quest Diagnostics solely to cover tax withholding obligations from that award settlement.
Separately, the filing notes indirect ownership of 5,737 shares through the company’s 401(k) and Supplemental Deferred Compensation Plan, with these plan holdings accumulated periodically by the plan trustee.